
PMID- 31768180
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220412
IS  - 1680-5348 (Electronic)
IS  - 1020-4989 (Linking)
VI  - 43
DP  - 2019
TI  - [Insulin: prices, availability, and affordability in public and private Peruvian 
      pharmaciesPreco, disponibilidade e acessibilidade a insulina em farmacias
      publicas e privadas no Peru].
PG  - e85
LID - 10.26633/RPSP.2019.85 [doi]
AB  - OBJECTIVE: Measure and compare the price, availability, and affordability of
      insulin and metformin in public and private pharmacies in six regions of Peru.
      METHODS: Cross-sectional study using the World Health Organization/Health Action 
      International (WHO/HAI) revised methodology. Public and private pharmacies in six
      regions of Peru were surveyed. Data were collected on availability and prices for
      insulin (all types) and 850 mg metformin. Availability is expressed as
      percentages and prices are reported in medians. Affordability is defined as the
      number of days that a person must work at minimum wage to cover the cost of one
      month of treatment. RESULTS: Availability in public pharmacies is 63.2% for
      regular insulin and 68.4% for NPH (isophane) insulin, but differences in
      availability were observed between levels of care and between regions. Private
      pharmacies have a greater variety of insulin, but availability is less than 11%. 
      The median price of human insulin was three to four times higher in private
      pharmacies than in public pharmacies. In comparison, availability of metformin
      was 89.5% in public pharmacies and 77.7% in private ones. Affordability in public
      pharmacies for one month of treatment with human insulin or generic metformin is 
      less than one day's wages. CONCLUSIONS: The price for human insulin and generic
      metformin in public pharmacies is affordable. However, efforts are needed to
      improve their availability in the different regions and levels of care.
FAU - Tenorio-Mucha, Janeth
AU  - Tenorio-Mucha J
AD  - Centro de Excelencia en Enfermedades Cronicas, CRONICAS Universidad Peruana
      Cayetano Heredia Lima Peru Centro de Excelencia en Enfermedades Cronicas,
      CRONICAS, Universidad Peruana Cayetano Heredia, Lima, Peru.
FAU - Lazo-Porras, Maria
AU  - Lazo-Porras M
AD  - Departamento de Medicina Tropical y Humanitaria Universidad de Ginebra y
      Hospitales Universitarios de Ginebra Ginebra Suiza Departamento de Medicina
      Tropical y Humanitaria, Universidad de Ginebra y Hospitales Universitarios de
      Ginebra, Ginebra, Suiza.
FAU - Hidalgo-Padilla, Liliana
AU  - Hidalgo-Padilla L
AD  - Centro de Excelencia en Enfermedades Cronicas, CRONICAS Universidad Peruana
      Cayetano Heredia Lima Peru Centro de Excelencia en Enfermedades Cronicas,
      CRONICAS, Universidad Peruana Cayetano Heredia, Lima, Peru.
FAU - Beran, David
AU  - Beran D
AD  - Departamento de Medicina Tropical y Humanitaria Universidad de Ginebra y
      Hospitales Universitarios de Ginebra Ginebra Suiza Departamento de Medicina
      Tropical y Humanitaria, Universidad de Ginebra y Hospitales Universitarios de
      Ginebra, Ginebra, Suiza.
FAU - Ewen, Margaret
AU  - Ewen M
AD  - Accion Internacional para la Salud Accion Internacional para la Salud Amsterdam
      Paises Bajos Accion Internacional para la Salud, Amsterdam, Paises Bajos.
LA  - spa
PT  - English Abstract
PT  - Journal Article
TT  - Precios, disponibilidad y asequibilidad de insulina en farmacias publicas y
      privadas en Peru.
DEP - 20191031
PL  - United States
TA  - Rev Panam Salud Publica
JT  - Revista panamericana de salud publica = Pan American journal of public health
JID - 9705400
PMC - PMC6822689
OTO - NOTNLM
OT  - Insulin
OT  - Peru
OT  - access to essential medicines and health technologies
OT  - drug price
OT  - metformin
COIS- Conflicto de intereses. Ninguno declarado por los autores.
EDAT- 2019/11/27 06:00
MHDA- 2019/11/27 06:01
CRDT- 2019/11/27 06:00
PHST- 2019/07/10 00:00 [received]
PHST- 2019/09/20 00:00 [accepted]
PHST- 2019/11/27 06:00 [entrez]
PHST- 2019/11/27 06:00 [pubmed]
PHST- 2019/11/27 06:01 [medline]
AID - 10.26633/RPSP.2019.85 [doi]
AID - RPSP.2019.85 [pii]
PST - epublish
SO  - Rev Panam Salud Publica. 2019 Oct 31;43:e85. doi: 10.26633/RPSP.2019.85.
      eCollection 2019.

PMID- 31695236
OWN - NLM
STAT- MEDLINE
DCOM- 20200330
LR  - 20200330
IS  - 0016-3813 (Print)
IS  - 0016-3813 (Linking)
VI  - 155
IP  - 5
DP  - 2019
TI  - El receptor soluble de insulina y el sindrome metabolico.
PG  - 541-545
LID - 10.24875/GMM.19005185 [doi]
AB  - The metabolic syndrome describes a group of signs that increase the likelihood
      for developing type 2 diabetes mellitus, cardiovascular diseases and some types
      of cancer. The action of insulin depends on its binding to membrane receptors on 
      its target cells. We wonder if blood insulin could travel bound to proteins and
      if, in the presence of hyperinsulinemia, a soluble insulin receptor might be
      generated. We used young adult Wistar rats (which have no predisposition to
      obesity or diabetes), whose drinking water was added 20 % of sugar and that were 
      fed a standard diet ad libitum for two and six months. They were compared with
      control rats under the same conditions, but that had running water for
      consumption. At two months, the rats developed central obesity, moderate
      hypertension, high triglyceride levels, hyperinsulinemia, glucose intolerance and
      insulin resistance, i.e. metabolic syndrome. Electrophoresis of the rats' plasma 
      proteins was performed, followed by Western Blot (WB) for insulin and for the
      outer portion of the insulin receptor. The bands corresponding to insulin and to 
      the receptor external part were at the same molecular weight level, 25-fold
      higher than that of free insulin. We demonstrated that insulin, both in control
      animals and in those with hyperinsulinemia, travels bound to the receptor outer
      portion (ectodomain), which we called soluble insulin receptor, and that is
      released al higher amounts in response to plasma insulin increase; in rats with
      metabolic syndrome and hyperinsulinemia, plasma levels are much higher than in
      controls. Soluble insulin receptor increase in blood might be an early sign of
      metabolic syndrome.
CI  - Copyright: (c) 2019 Permanyer.
FAU - Hiriart-Urdanivia, Marcia
AU  - Hiriart-Urdanivia M
AD  - Universidad Nacional Autonoma de Mexico, Instituto de Fisiologia Celular,
      Departamento de Neurociencia Cognitiva, Ciudad de Mexico, Mexico.
FAU - Sanchez-Soto, Carmen
AU  - Sanchez-Soto C
AD  - Universidad Nacional Autonoma de Mexico, Instituto de Fisiologia Celular,
      Departamento de Neurociencia Cognitiva, Ciudad de Mexico, Mexico.
FAU - Velasco, Myrian
AU  - Velasco M
AD  - Universidad Nacional Autonoma de Mexico, Instituto de Fisiologia Celular,
      Departamento de Neurociencia Cognitiva, Ciudad de Mexico, Mexico.
FAU - Sabido-Barrera, Jean
AU  - Sabido-Barrera J
AD  - Universidad Nacional Autonoma de Mexico, Instituto de Fisiologia Celular,
      Departamento de Neurociencia Cognitiva, Ciudad de Mexico, Mexico.
FAU - Ortiz-Huidobro, Rosa Isela
AU  - Ortiz-Huidobro RI
AD  - Universidad Nacional Autonoma de Mexico, Instituto de Fisiologia Celular,
      Departamento de Neurociencia Cognitiva, Ciudad de Mexico, Mexico.
LA  - eng
PT  - Journal Article
PL  - Mexico
TA  - Gac Med Mex
JT  - Gaceta medica de Mexico
JID - 0010333
RN  - 0 (Antigens, CD)
RN  - 0 (Insulin)
RN  - EC 2.7.10.1 (INSR protein, human)
RN  - EC 2.7.10.1 (Receptor, Insulin)
SB  - IM
MH  - Animals
MH  - Antigens, CD/*blood/physiology
MH  - Blotting, Western
MH  - Diabetes Mellitus, Type 2/etiology
MH  - Disease Models, Animal
MH  - Electrophoresis
MH  - Hyperinsulinism/blood
MH  - Insulin/*blood/physiology
MH  - Insulin Resistance
MH  - Metabolic Syndrome/*blood/etiology
MH  - Rats
MH  - Rats, Wistar
MH  - Receptor, Insulin/*blood/physiology
OTO - NOTNLM
OT  - Hiperinsulinemia
OT  - Hyperinsulinemia
OT  - Insulin resistance
OT  - Receptor soluble de insulina
OT  - Resistencia a la insulina
OT  - Soluble insulin receptor
EDAT- 2019/11/07 06:00
MHDA- 2020/03/31 06:00
CRDT- 2019/11/08 06:00
PHST- 2019/11/08 06:00 [entrez]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2020/03/31 06:00 [medline]
AID - j155/5/541 [pii]
AID - 10.24875/GMM.19005185 [doi]
PST - ppublish
SO  - Gac Med Mex. 2019;155(5):541-545. doi: 10.24875/GMM.19005185.

PMID- 31093264
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220411
IS  - 1680-5348 (Electronic)
IS  - 1020-4989 (Linking)
VI  - 43
DP  - 2019
TI  - [Consumption of red and processed meat, insulin resistance, and diabetes in the
      Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)Consumo de carnes rojas
      y de carne procesada, resistencia a la insulina y diabetes en el estudio
      longitudinal de salud del adulto (ELSA-Brasil)].
PG  - e40
LID - 10.26633/RPSP.2019.40 [doi]
AB  - OBJECTIVE: To investigate the association between red and processed meat
      consumption and the occurrence of new cases of insulin resistance (IR) and
      diabetes mellitus (DM) in participants of the Brazilian Longitudinal Study of
      Adult Health (ELSA-Brasil). METHOD: This cohort study included 15 105 civil
      servants (age: 35-74 years). Biochemical, anthropometric, and socioeconomic data,
      as well as lifestyle characteristics, were collected at baseline (2008-2010) and 
      wave 2 (2012-2014). Meat consumption (g/day) was estimated using a food frequency
      questionnaire. To categorize low, medium, and high consumption, independent
      variables were divided into tertiles. DM was diagnosed as fasting glucose >/= 126
      mg/dL, postload glucose >/= 200 mg/dL, or glycated hemoglobin >/= 6.5. IR was
      determined by HOMA-IR with cutoff points based on the sample's 75th percentile.
      RESULTS: Men and participants with lower income and schooling reported higher
      consumption of red and processed meat. High consumption of processed meat
      (highest tertile, > 27.1 g/day) was associated with new cases of IR in men (OR = 
      1.68; 95%CI: 1.31-2.16) and women (OR = 1.23; 95%CI: 1.00-1>52). High consumption
      of red meat increased by 40% (95%CI: 1.04-1.96) the likelihood of new cases of DM
      in men. CONCLUSIONS: High consumption of red/processed meat negatively impacted
      the health of participants. Moderate consumption of meats may be recommended for 
      the general population and for prevention of DM.
FAU - Aprelini, Carla Moronari de Oliveira
AU  - Aprelini CMO
AD  - Programa de Pos-Graduacao em Saude Coletiva Programa de Pos-Graduacao em Saude
      Coletiva Universidade Federal do Espirito Santo VitoriaES Brasil Universidade
      Federal do Espirito Santo, Programa de Pos-Graduacao em Saude Coletiva, Vitoria
      (ES), Brasil.
FAU - Luft, Vivian Cristine
AU  - Luft VC
AD  - Programa de Pos-Graduacao em Epidemiologia Programa de Pos-Graduacao em
      Epidemiologia Universidade Federal do Rio Grande do Sul (UFRGS) Porto AlegreRS
      Brasil Universidade Federal do Rio Grande do Sul (UFRGS), Programa de
      Pos-Graduacao em Epidemiologia, Porto Alegre (RS), Brasil.
FAU - Melendez, Gustavo Velasquez
AU  - Melendez GV
AD  - Escola de Enfermagem Escola de Enfermagem Universidade Federal de Minas Gerais
      (UFMG) Belo HorizonteMG Brasil Universidade Federal de Minas Gerais (UFMG),
      Escola de Enfermagem, Belo Horizonte (MG), Brasil.
FAU - Schmidt, Maria Ines
AU  - Schmidt MI
AD  - Programa de Pos-Graduacao em Epidemiologia Programa de Pos-Graduacao em
      Epidemiologia Universidade Federal do Rio Grande do Sul (UFRGS) Porto AlegreRS
      Brasil Universidade Federal do Rio Grande do Sul (UFRGS), Programa de
      Pos-Graduacao em Epidemiologia, Porto Alegre (RS), Brasil.
FAU - Mill, Jose Geraldo
AU  - Mill JG
AD  - Programa de Pos-Graduacao em Saude Coletiva Programa de Pos-Graduacao em Saude
      Coletiva Universidade Federal do Espirito Santo VitoriaES Brasil Universidade
      Federal do Espirito Santo, Programa de Pos-Graduacao em Saude Coletiva, Vitoria
      (ES), Brasil.
FAU - Molina, Maria Del Carmen Bisi
AU  - Molina MDCB
AD  - Programa de Pos-Graduacao em Saude Coletiva Programa de Pos-Graduacao em Saude
      Coletiva Universidade Federal do Espirito Santo VitoriaES Brasil Universidade
      Federal do Espirito Santo, Programa de Pos-Graduacao em Saude Coletiva, Vitoria
      (ES), Brasil.
LA  - por
PT  - English Abstract
PT  - Journal Article
TT  - Consumo de carne vermelha e processada, resistencia insulinica e diabetes no
      Estudo Longitudinal de Saude do Adulto (ELSA-Brasil).
DEP - 20190503
PL  - United States
TA  - Rev Panam Salud Publica
JT  - Revista panamericana de salud publica = Pan American journal of public health
JID - 9705400
PMC - PMC6499085
OTO - NOTNLM
OT  - Brazil
OT  - Red meat
OT  - diabetes mellitus
OT  - insulin resistance
OT  - meat products
COIS- Conflito de interesses. Nada declarado pelos autores.
EDAT- 2019/05/17 06:00
MHDA- 2019/05/17 06:01
CRDT- 2019/05/17 06:00
PHST- 2018/07/21 00:00 [received]
PHST- 2019/02/25 00:00 [accepted]
PHST- 2019/05/17 06:00 [entrez]
PHST- 2019/05/17 06:00 [pubmed]
PHST- 2019/05/17 06:01 [medline]
AID - 10.26633/RPSP.2019.40 [doi]
AID - RPSP.2019.40 [pii]
PST - epublish
SO  - Rev Panam Salud Publica. 2019 May 3;43:e40. doi: 10.26633/RPSP.2019.40.
      eCollection 2019.

PMID- 31087451
OWN - NLM
STAT- MEDLINE
DCOM- 20200413
LR  - 20200413
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
VI  - 36
IP  - 8
DP  - 2019 Aug
TI  - Assessment of Alimentacion Normal con Ajuste de Insulina (ANAIS), a Spanish
      version of the DAFNE programme, in people with Type 1 diabetes: a randomized
      controlled parallel trial.
PG  - 1037-1045
LID - 10.1111/dme.13984 [doi]
AB  - AIM: To evaluate the effects of Alimentacion Normal con Ajuste de Insulina
      (ANAIS), a group-based, therapeutic education programme for Type 1 diabetes based
      on a flexible insulin regimen adjusted to the individual's food intake. METHODS: 
      Participants with Type 1 diabetes and HbA1c levels of 53-86 mmol/mol (7-10%) were
      recruited from outpatient clinics at a tertiary care centre. They were randomized
      (using opaque, sealed envelopes, with a 2:1 treatment allocation ratio) to attend
      the training course immediately (immediate ANAIS; intervention group) or a year
      later (delayed ANAIS; control group). The main outcome was HbA1c level at 1 year.
      Secondary outcomes included lipid levels, weight, hypoglycaemic events, insulin
      dose, treatment satisfaction, self-perceived dietary freedom, quality of life and
      participant-defined goals. RESULTS: A total of 48 participants were assigned to
      the intervention group and 32 to the control group. Twelve months after
      completing the training, adjusted HbA1c was not significantly different in the
      intervention group [64 +/- 1.3 vs 68 +/- 1.6 mmol/mol (8.0 +/-0.1% vs 8.4
      +/-0.1%); P=0.081]. Treatment satisfaction was significantly higher in the
      intervention group, but no differences were found in hypoglycaemic events,
      weight, insulin dose or changes in dietary freedom. At 1 year after the
      intervention, 72% of the participants (vs 33% in the control group; P=0.046)
      reported exceeding their expectations regarding achievement of their main
      personal goal. CONCLUSION: Promoting dietary freedom and empowering people with
      Type 1 diabetes through structured education programmes, such as ANAIS, improves 
      treatment satisfaction and self-defined goals. No significant improvement in
      HbA1c level was achieved.
CI  - (c) 2019 Diabetes UK.
FAU - Sanchez-Hernandez, R M
AU  - Sanchez-Hernandez RM
AD  - Department of Endocrinology and Nutrition, University Hospital Insular
      Materno-Infantil, Las Palmas de Gran Canaria, Spain.
AD  - Institute of Biomedical and Health Research (IUIBS). University of Las Palmas de 
      Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain.
FAU - Alvarado-Martel, D
AU  - Alvarado-Martel D
AUID- ORCID: 0000-0003-4952-4115
AD  - Department of Endocrinology and Nutrition, University Hospital Insular
      Materno-Infantil, Las Palmas de Gran Canaria, Spain.
AD  - Institute of Biomedical and Health Research (IUIBS). University of Las Palmas de 
      Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain.
FAU - Lopez-Plasencia, Y
AU  - Lopez-Plasencia Y
AD  - Department of Endocrinology and Nutrition, University Hospital Insular
      Materno-Infantil, Las Palmas de Gran Canaria, Spain.
AD  - Institute of Biomedical and Health Research (IUIBS). University of Las Palmas de 
      Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain.
FAU - Carrillo-Dominguez, A
AU  - Carrillo-Dominguez A
AD  - Department of Endocrinology and Nutrition, University Hospital Insular
      Materno-Infantil, Las Palmas de Gran Canaria, Spain.
AD  - Institute of Biomedical and Health Research (IUIBS). University of Las Palmas de 
      Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain.
FAU - Jimenez-Rodriguez, A
AU  - Jimenez-Rodriguez A
AD  - Department of Endocrinology and Nutrition, University Hospital Insular
      Materno-Infantil, Las Palmas de Gran Canaria, Spain.
FAU - Rodriguez-Cordero, J
AU  - Rodriguez-Cordero J
AD  - Department of Endocrinology and Nutrition, University Hospital Insular
      Materno-Infantil, Las Palmas de Gran Canaria, Spain.
FAU - Vera-Elzo, T
AU  - Vera-Elzo T
AD  - Diabetes Association of Gran Canaria, Las Palmas de Gran Canaria, Spain.
FAU - Santana Del Pino, A
AU  - Santana Del Pino A
AD  - Department of Mathematics and Statistics, University of Las Palmas de Gran
      Canaria, Las Palmas de Gran Canaria, Spain.
FAU - Novoa-Mogollon, F J
AU  - Novoa-Mogollon FJ
AD  - Department of Endocrinology and Nutrition, University Hospital Insular
      Materno-Infantil, Las Palmas de Gran Canaria, Spain.
AD  - Institute of Biomedical and Health Research (IUIBS). University of Las Palmas de 
      Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain.
FAU - Wagner, A M
AU  - Wagner AM
AUID- ORCID: 0000-0002-7663-9308
AD  - Department of Endocrinology and Nutrition, University Hospital Insular
      Materno-Infantil, Las Palmas de Gran Canaria, Spain.
AD  - Institute of Biomedical and Health Research (IUIBS). University of Las Palmas de 
      Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20190613
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Adult
MH  - Body Weight/physiology
MH  - Clinical Protocols
MH  - Diabetes Mellitus, Type 1/blood/*therapy
MH  - Energy Intake
MH  - Female
MH  - Glycated Hemoglobin A/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Male
MH  - Patient Education as Topic/*methods
MH  - Psychotherapy/*methods
MH  - Treatment Outcome
EDAT- 2019/05/16 06:00
MHDA- 2020/04/14 06:00
CRDT- 2019/05/16 06:00
PHST- 2019/05/10 00:00 [accepted]
PHST- 2019/05/16 06:00 [pubmed]
PHST- 2020/04/14 06:00 [medline]
PHST- 2019/05/16 06:00 [entrez]
AID - 10.1111/dme.13984 [doi]
PST - ppublish
SO  - Diabet Med. 2019 Aug;36(8):1037-1045. doi: 10.1111/dme.13984. Epub 2019 Jun 13.

PMID- 31056606
OWN - NLM
STAT- MEDLINE
DCOM- 20191107
LR  - 20220408
IS  - 0016-3813 (Print)
IS  - 0016-3813 (Linking)
VI  - 155
IP  - 2
DP  - 2019
TI  - Inercia clinica en el tratamiento con insulina en el primer nivel de atencion.
PG  - 156-161
LID - 10.24875/GMM.19004582 [doi]
AB  - INTRODUCTION: Refusal of physicians to prescribe insulin to their patients has
      been scarcely evaluated; the delay in treatment intensification hinders adequate 
      and quality care. OBJECTIVE: To identify the perception of primary care
      physicians about barriers to initiate insulin treatment in patients with
      diabetes. METHOD: Using the Smith Index and multivariate analysis, the relevance 
      and grouping of concepts related to barriers to insulin prescription were
      assessed in 81 family doctors. RESULTS: Only 35.8% of physicians showed
      confidence for prescribing insulin; almost half of them rated treatment
      intensification between moderately and little important (39.5% and 6.2%).
      Barriers were related to the physician (39.5%), the patient (37%), insulin
      treatment (11.1%) and the institution (6.2%); 6.2 % of physicians did not
      perceive any barrier. The barriers were grouped in 5 factors that explained
      62.48% of the variance: patient cultural level, lack of medical skills, fear of
      adverse events, insecurity and lack of training. CONCLUSION: Clinical inertia was
      not the result of a complex medical condition or patient comorbidities, but of
      doctor's perception and confidence in his/her clinical and communication skills.
CI  - Copyright: (c) 2019 SecretarIa de Salud.
FAU - Vazquez, Felipe
AU  - Vazquez F
AD  - Secretaria de Salud, Servicios de Atencion Psiquiatrica. Ciudad de Mexico,
      Mexico. Ciudad de Mexico, Mexico.
FAU - Lavielle, Pilar
AU  - Lavielle P
AD  - Instituto Mexicano del Seguro Social, Centro Medico Nacional Siglo XXI, Hospital 
      de Especialidades, Unidad de Investigacion en Epidemiologia Clinica. Ciudad de
      Mexico, Mexico.
FAU - Gomez-Diaz, Rita
AU  - Gomez-Diaz R
AD  - Instituto Mexicano del Seguro Social, Centro Medico Nacional Siglo XXI, Hospital 
      de Especialidades, Unidad de Investigacion en Epidemiologia Clinica. Ciudad de
      Mexico, Mexico.
FAU - Wacher, Niels
AU  - Wacher N
AD  - Instituto Mexicano del Seguro Social, Centro Medico Nacional Siglo XXI, Hospital 
      de Especialidades, Unidad de Investigacion en Epidemiologia Clinica. Ciudad de
      Mexico, Mexico.
LA  - eng
PT  - Journal Article
PL  - Mexico
TA  - Gac Med Mex
JT  - Gaceta medica de Mexico
JID - 0010333
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Attitude of Health Personnel
MH  - Clinical Competence
MH  - Communication
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Insulin/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Physicians, Primary Care/*statistics & numerical data
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Quality of Health Care
OTO - NOTNLM
OT  - Atencion primaria
OT  - Barreras
OT  - Barriers
OT  - Clinical inertia
OT  - Inercia clinica
OT  - Insulin treatment
OT  - Primary care
OT  - Tratamiento con insulina
EDAT- 2019/05/06 06:00
MHDA- 2019/11/08 06:00
CRDT- 2019/05/07 06:00
PHST- 2019/05/07 06:00 [entrez]
PHST- 2019/05/06 06:00 [pubmed]
PHST- 2019/11/08 06:00 [medline]
AID - j155/2/156 [pii]
AID - 10.24875/GMM.19004582 [doi]
PST - ppublish
SO  - Gac Med Mex. 2019;155(2):156-161. doi: 10.24875/GMM.19004582.

PMID- 30532124
OWN - NLM
STAT- MEDLINE
DCOM- 20191003
LR  - 20220410
IS  - 0016-3813 (Print)
IS  - 0016-3813 (Linking)
VI  - 154
IP  - Supp 2
DP  - 2018
TI  - [Indices para la evaluacion de la resistencia a la insulina en individuos
      mexicanos sin diabetes].
PG  - S50-S55
LID - 10.24875/GMM.18004578 [doi]
AB  - OBJECTIVE: To evaluate the correlation between subrogate index for the evaluation
      of insulin resistance with the M value obtained with the
      euglycemic-hyperinsulinemic clamp as well as their sensitivity, specificity, and 
      positive and negative predictive values. METHOD: The euglycemic-hyperinsulinemic 
      clamp was performed in subjects having both normal fasting glucose and glycated
      hemoglobin concentrations. HOMA-IR, QUICKI, HOMA2%S, TyG, TyG*body mass index
      (BMI) and triglyceride/HDL indexes were calculated. Correlations coefficients
      were estimated between indexes results and the M-value adjusted by fat-free mass.
      Areas under the ROC curve were constructed to evaluate overall performance,
      sensitivity, specificity and predictive values of the subrogate indexes. RESULTS:
      57 subjects, 68.4% women, with a mean age of 32.9 +/- 11 years-old were included.
      The subrogate index with the best correlation with the M value was HOMA2%S (r =
      0.428), HOMA-IR had the greatest area under the ROC curve (0.683; 95 % confidence
      interval: 0.503-0.864) and TyG*BMI the best sensitivity (98.2 %) and specificity 
      (51.1 %). CONCLUSIONS: The surrogated indexes for the evaluation of insulin
      resistance show a significant correlation with the M value obtained with the gold
      standard. Additional studies are required to determine cut-off values in Mexican 
      population.
CI  - Copyright: (c) 2018 SecretarIa de Salud.
FAU - Almeda-Valdes, Paloma
AU  - Almeda-Valdes P
AD  - Departamento de Endocrinologia y Metabolismo, Ciudad de Mexico, Mexico.
AD  - Unidad de Investigacion de Enfermedades Metabolicas. Instituto Nacional de
      Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Mexico.
FAU - Bello-Chavolla, Omar Y
AU  - Bello-Chavolla OY
AD  - Unidad de Investigacion de Enfermedades Metabolicas. Instituto Nacional de
      Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Mexico.
AD  - Programa PECEM, Facultad de Medicina, Universidad Nacional Autonoma de Mexico,
      Ciudad de Mexico, Mexico.
FAU - Caballeros-Barragan, Cesar R
AU  - Caballeros-Barragan CR
AD  - Departamento de Endocrinologia y Metabolismo, Ciudad de Mexico, Mexico.
FAU - Gomez-Velasco, Donaji V
AU  - Gomez-Velasco DV
AD  - Unidad de Investigacion de Enfermedades Metabolicas. Instituto Nacional de
      Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Mexico.
FAU - Viveros-Ruiz, Tania
AU  - Viveros-Ruiz T
AD  - Unidad de Investigacion de Enfermedades Metabolicas. Instituto Nacional de
      Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Mexico.
FAU - Vargas-Vazquez, Arsenio
AU  - Vargas-Vazquez A
AD  - Unidad de Investigacion de Enfermedades Metabolicas. Instituto Nacional de
      Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Mexico.
AD  - Programa PECEM, Facultad de Medicina, Universidad Nacional Autonoma de Mexico,
      Ciudad de Mexico, Mexico.
FAU - Aguilar-Salinas, Carlos A
AU  - Aguilar-Salinas CA
AD  - Departamento de Endocrinologia y Metabolismo, Ciudad de Mexico, Mexico.
AD  - Unidad de Investigacion de Enfermedades Metabolicas. Instituto Nacional de
      Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Mexico.
LA  - spa
PT  - Journal Article
PL  - Mexico
TA  - Gac Med Mex
JT  - Gaceta medica de Mexico
JID - 0010333
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (HDL-triglyceride)
RN  - 0 (Lipoproteins, HDL)
RN  - 0 (Triglycerides)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/*metabolism
MH  - *Body Mass Index
MH  - Cross-Sectional Studies
MH  - Fasting
MH  - Female
MH  - Glucose Clamp Technique
MH  - Glycated Hemoglobin A/*metabolism
MH  - Humans
MH  - Insulin Resistance/*physiology
MH  - Lipoproteins, HDL/metabolism
MH  - Male
MH  - Mexico
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - ROC Curve
MH  - Sensitivity and Specificity
MH  - Triglycerides/metabolism
MH  - Young Adult
OTO - NOTNLM
OT  - Euglycemic-hyperinsulinemic clamp
OT  - HOMA-IR
OT  - HOMA2%S
OT  - Pinza euglucemica-hiperinsulinemica
OT  - QUICKI
OT  - TG/HDL index
OT  - TyG index
OT  - Indice TG/HDL
OT  - Indice TyG
EDAT- 2018/12/12 06:00
MHDA- 2019/10/08 06:00
CRDT- 2018/12/12 06:00
PHST- 2018/12/12 06:00 [entrez]
PHST- 2018/12/12 06:00 [pubmed]
PHST- 2019/10/08 06:00 [medline]
AID - j154/S2/S50 [pii]
AID - 10.24875/GMM.18004578 [doi]
PST - ppublish
SO  - Gac Med Mex. 2018;154(Supp 2):S50-S55. doi: 10.24875/GMM.18004578.

PMID- 29414963
OWN - NLM
STAT- MEDLINE
DCOM- 20190130
LR  - 20190130
IS  - 0016-3813 (Print)
IS  - 0016-3813 (Linking)
VI  - 153
IP  - 7
DP  - 2017
TI  - El papel de los acidos grasos libres en la resistencia a la insulina.
PG  - 852-863
LID - 10.24875/GMM.17002714 [doi]
AB  - Free fatty acids are essential nutritional components and recent studies
      identified them as signaling molecules in various physiological processes. It has
      now been shown that high levels of free fatty acids, particularly saturated fatty
      acids, may be associated with insulin resistance in obese patients with type 2
      diabetes mellitus. Insulin resistance is important in clinical since it is
      related to various diseases including type 2 diabetes mellitus, dyslipidemia, and
      abnormalities at cardiovascular level. Recent studies have proposed different
      molecular mechanisms by which these lipids may alter the signaling pathway of
      insulin. The purpose of this review is to highlight recent advances in the study 
      of the effect of free fatty acids as modulators of insulin response.
CI  - Copyright: (c) 2017 SecretarIa de Salud.
FAU - Vazquez-Jimenez, Jose Gustavo
AU  - Vazquez-Jimenez JG
AD  - Departamento de Fisiologia, Escuela de Medicina, Universidad Autonoma de Baja
      California, Mexicali, B.C., Mexico.
FAU - Roura-Guiberna, Adriana
AU  - Roura-Guiberna A
AD  - Laboratorio de Transduccion de Senales, Departamento de Bioquimica, Centro de
      Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Ciudad 
      de Mexico, Mexico.
FAU - Jimenez-Mena, Luisa Reyna
AU  - Jimenez-Mena LR
AD  - Laboratorio de Transduccion de Senales, Departamento de Bioquimica, Centro de
      Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Ciudad 
      de Mexico, Mexico.
FAU - Olivares-Reyes, Jesus Alberto
AU  - Olivares-Reyes JA
AD  - Laboratorio de Transduccion de Senales, Departamento de Bioquimica, Centro de
      Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Ciudad 
      de Mexico, Mexico.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Mexico
TA  - Gac Med Mex
JT  - Gaceta medica de Mexico
JID - 0010333
RN  - 0 (Ceramides)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Insulin)
RN  - 0 (Toll-Like Receptors)
RN  - EC 2.7.- (Protein Kinases)
SB  - IM
MH  - Cardiovascular Diseases/etiology
MH  - Ceramides/metabolism
MH  - Diabetes Mellitus, Type 2/etiology
MH  - Dyslipidemias/etiology
MH  - Endoplasmic Reticulum Stress/physiology
MH  - Fatty Acids, Nonesterified/*physiology
MH  - Humans
MH  - Insulin/*physiology
MH  - Insulin Resistance/*physiology
MH  - Obesity
MH  - Oxidative Stress/physiology
MH  - Protein Kinases/metabolism
MH  - Toll-Like Receptors/metabolism
OTO - NOTNLM
OT  - Fatty acids
OT  - Insulin receptor
OT  - Insulin receptor substrate
OT  - Insulin resistance
EDAT- 2018/02/08 06:00
MHDA- 2019/01/31 06:00
CRDT- 2018/02/08 06:00
PHST- 2018/02/08 06:00 [entrez]
PHST- 2018/02/08 06:00 [pubmed]
PHST- 2019/01/31 06:00 [medline]
AID - j153/7/852 [pii]
AID - 10.24875/GMM.17002714 [doi]
PST - ppublish
SO  - Gac Med Mex. 2017;153(7):852-863. doi: 10.24875/GMM.17002714.

PMID- 25977105
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150515
LR  - 20150515
IS  - 0873-2159 (Print)
IS  - 0873-2159 (Linking)
VI  - 13
IP  - 4
DP  - 2007 Jul-Aug
TI  - Terapeutica clinica - Insulina inalada para a diabetes mellitus.
PG  - 639-41
LID - 10.1016/S0873-2159(15)30373-1 [doi]
LID - S0873-2159(15)30373-1 [pii]
FAU - McMahon, Graham T
AU  - McMahon GT
FAU - Arky, Ronald A
AU  - Arky RA
LA  - eng
LA  - por
PT  - Journal Article
PL  - Spain
TA  - Rev Port Pneumol
JT  - Revista portuguesa de pneumologia
JID - 9813736
EDAT- 2007/07/01 00:00
MHDA- 2007/07/01 00:01
CRDT- 2015/05/16 06:00
PHST- 2015/05/16 06:00 [entrez]
PHST- 2007/07/01 00:00 [pubmed]
PHST- 2007/07/01 00:01 [medline]
AID - S0873-2159(15)30373-1 [pii]
AID - 10.1016/S0873-2159(15)30373-1 [doi]
PST - ppublish
SO  - Rev Port Pneumol. 2007 Jul-Aug;13(4):639-41. doi: 10.1016/S0873-2159(15)30373-1.
